Sigyn Therapeutics (OTCMKTS:SIGY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both small-cap medical companies, but which is the superior investment? Analyst RatingsThis is a summary of current ratings for Sigyn Therapeutics and Reviva Pharmaceuticals, as provided by MarketBeat.com. Get Sigyn Therapeutics alerts:Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sigyn Therapeutics 0 0 0 0 0.00 Reviva Pharmaceuticals 0 0 8 0 3.00Reviva Pharmaceuticals has a consensus price target of $4.86, indicating a potential upside of 1,217.73%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Sigyn Therapeutics. Valuation & EarningsGross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sigyn Therapeutics N/A N/A -$3.34 million ($4.77) -0.79 Reviva Pharmaceuticals N/A N/A -$29.92 million ($0.65) -0.57This table compares Sigyn Therapeutics and Reviva Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.